Site Search
This three-day virtual conference offered for just a few hours each day will offer the opportunity to learn techniques for managing burnout and ways to create a positive patient experience. Attendees will have the option to select from a...
Ulcerative Colitis and Crohn Disease Therapeutic Drug Monitoring Algorithm
This algorithm guides testing for initiation of biologic therapy and therepeutic drug monitoring for patients diagnosed with ulcerative colitis or Crohn disease.
Light Protection Tests - Mayo Clinic Laboratories
Test Catalog AlgorithmsDownload Test Catalog & Interpretive HandbookNew TestsNY State Informed Consent TestsPerforming LocationsReferred TestsSpecialty TestingTest Updates...
Newborn Screen Follow-up for Elevated C16 +/- C18:1 Acylcarnitines
This algorithm guides follow-up testing when elevated C16 and a possible elevation of C18:1 acylcarnitine were detected by newborn screening.
Difficult Collections and Special Populations
Difficult Collections and Special Populations Difficult Collections and Special Populations You are offline. Trying to reconnect...
Advanced Phlebotomy Collections
Advanced Phlebotomy Collections Advanced Phlebotomy Collections You are offline. Trying to reconnect...
Fundamentals of Phlebotomy Fundamentals of Phlebotomy You are offline. Trying to reconnect...
Introduction to Phlebotomy Introduction to Phlebotomy You are offline. Trying to reconnect...
Biologic Therapy Testing - Mayo Clinic Laboratories
To monitor for immunogenicity, our reflexive approach first measures the biologic concentration within a patient’s specimen. Then, if necessary, an additional test is performed to assess the presence of antibodies to a specific drug that...
Urinary Steroid Profile [Test in Focus] - Insights
Irina Bancos, M.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken...
Next-generation sequencing: Examining an often oversimplified & misunderstood technology--Part I
In the last decade, genetic testing has evolved from single-gene Sanger based assays to much more complex next-generation sequencing (NGS) based assays.
Hereditary testing by specialty - Insights
Mayo Clinic Laboratories is a one-stop laboratory for hereditary testing, featuring a robust menu of molecular, cytogenic, biochemical, and functional assays that support diagnosis and care.
Scaling Knowledge With AI: Bill Morice, M.D., Ph.D. - Insights
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss how...
Test Classification Updates - Mayo Clinic Laboratories
Test Catalog AlgorithmsDownload Test Catalog & Interpretive HandbookNew TestsNY State Informed Consent TestsPerforming LocationsReferred TestsSpecialty TestingTest Updates...
Newborn Screen Follow-up for Elevated C16-OH +/- C18-OH
This algorithm guides follow-up testing when elevated C16 and a possible elevation of C18:OH acylcarnitine were detected by newborn screening.
Newborn Screen Follow-up for Elevated C0, C0/C16+C18
This algorithm guides follow-up testing for elevated or normal free carnitine with elevated C0/C16+C18 ratio were detected by newborn screening.
Zhiyv (Neal) Niu, Ph.D., and Christopher Klein, M.D., explain how Mayo Clinic Laboratories' updated neuromuscular gene panel informs diagnosis and treatment. The phenotype-based panel covers the complete list of neuromuscular genes and...
Exploratory testing - Insights
Mayo Clinic Laboratories’ whole exome and whole genome sequencing assays provide in-depth interrogation of all the genes in the human genome, offering individualized insights for optimal outcomes.
Mayo Clinic physicians and scientists drive research and test development, and our assays are backed by some of the world’s leading subspecialists.
PACE/State of FL - The critical role of pharmacogenomics and therapeutic drug monitoring (TDM) in managing immunosuppressive therapy for solid organ transplant recipients.
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in...
Quantitative Adenovirus Assay Better Informs Post-Transplant Care: Joseph Yao, M.D. - Insights
Joseph Yao, M.D., explains how Mayo Clinic Laboratories' new quantitative assay (Mayo ID: ADVQU) goes beyond qualitative testing to evaluate transplant patients for adenovirus infection. Adenovirus can cause life-threatening disease in...
Paraneoplastic Vision Loss Evaluation [Test in Focus] - Insights
Andrew McKeon, M,B., B.Ch., M.D., provides an overview of Mayo Clinic Laboratories' new paraneoplastic vision loss evaluation — a test that can help direct a cancer diagnosis and guide treatment. He reviews why this test was developed, when...
Kelch-11 Autoantibody Test [Test in Focus] - Insights
Divyanshu (Div) Dubey, M.B.B.S., explains how Mayo Clinic Labs’ new Kelch-11 antibody test — the first in the world — can confirm diagnosis, guide treatment, and improve outcomes in patients affected by testicular cancer-associated...
Improving diagnosis and treatment of Helicobacter pylori - Insights
Mayo Clinic Laboratories now offers a noninvasive approach for the molecular detection of H. pylori, with results that include prediction of clarithromycin resistance delivered within 24 hours.
Gastrointestinal Pathology Service at Mayo Clinic Laboratories
In our practice, we review both luminal GI tract specimens and solid viscera. We cover the spectrum of pathology from routine to highly esoteric.
Breast Pathology Services at Mayo Clinic Laboratories
Given our case volume, we've developed a special expertise in those rare variants of carcinoma, where the diagnosis is essential. Learn more.
Updated testing algorithms for plasma cell proliferative disorders [Test in Focus] - Insights
Xinjie Xu, Ph.D., co-director of Mayo's Genetics and Genomics Laboratory, explains Mayo Clinic Laboratories' updated approach to testing for risk stratification of patients newly diagnosed with plasma cell proliferative disorders, such as...
Alpha-gal testing [Test in Focus] - Insights
Joshua Bornhorst, Ph.D., associate director of Mayo Clinic's Clinical Immunoassay Lab, explains how humans can develop an allergy to the alpha-gal molecule, and he describes a new allergen antibody test that can be used to detect it. Dr....
New tests launched in July - Insights
In July 2022, Mayo Clinic Laboratories announced fifteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Learn how our testing identifies genetic and autoimmune causes of epilepsy. Accurate diagnosis helps physicians identify potential treatment options.
Neurodevelopmental disorders - Insights
Learn more about how chromosomal microarray can be used as a first-tier diagnostic test for those with congenital abnormalities and developmental disabilities.
Whole exome sequencing - Insights
Learn more about how whole exome sequencing at Mayo Clinic Laboratories can quickly end diagnostic testing odysseys for patients with suspected genetic disorders.
Anatomic Pathology
Clinical Pathology
Answers From the Lab Archives - Page 2 of 28 - Insights
Skip to Content MayoACCESS MayoLINK Register My Dashboard...
With the rise of next generation sequencing (NGS) technology, multigene panel testing is expanding so rapidly that clinical practice is racing to keep pace. And questions within genetic tests have expanded along with it, making definitive...
MDM2 gene amplification [Test in Focus] - Insights
William Sukov, M.D., provides an overview of the MDM2 gene amplification assay — a test that looks for amplification of the MDM2 gene region on chromosome 12q. He reviews when this test should be ordered, how it compares to other test...
Therapeutics events - Insights
TherapeuticS Creating the new standard of therapeutic management, together Mayo Clinic Laboratories’ evidence-based toxicology and pharmacogenomic testing
Plasma Cell Proliferative Disorder [Test in Focus] - Insights
Linda Baughn Ph.D. gives an overview of this new test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be...
Carrier Screening [Test in Focus] - Insights
Michelle Kluge, M.S., CGC, explains how Mayo Clinic Laboratories’ CYPZ assay provides accurate testing for congenital adrenal hyperplasia. Using an in-depth methodology that incorporates Sanger sequencing, MCL can provide clear answers for...
Examining dendritic cells to uncover immunity defects - Insights
Dendritic cells play a crucial role in the body's immune response. Research has shown that too few of these cells in the blood may signal a defect in innate immunity. Up to this point, however, no clinical test has been available to count...
New Tests Launched in August - Insights
In August 2020, Mayo Clinic Laboratories announced five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
B-cell lymphoblastic leukemia monitoring for minimal residual disease [Test in Focus] - Insights
Min Shi, M.D., Ph.D., a hematologist and co-director of Mayo Clinic's Flow Cytometry Laboratory, explains recent updates to the B-cell lymphoblastic leukemia minimal residual disease flow cytometry assay. This test is used to identify...
Developed through evidence-driven clinical innovation and designed to deliver clarity on drug and alcohol use, our testing delivers results that advance understanding and improve outcomes.
TPMT Testing in Treatment of Inflammatory Bowel Disease [Test in Focus] - Insights
Detection of individuals with low thiopurine methyltransferase (TPMT) activity who are at risk for excessive myelosuppression or severe hematopoietic toxicity when taking thiopurine drugs.
Pancreatic Elastase - Insights
Puanani Hopson, D.O., a Mayo Clinic pediatric gastroenterologist, explains the pancreatic elastase test — a screening test that can be useful when symptoms point to the possibility of exocrine pancreatic insufficiency. Dr. Hopson reviews...
Autoimmune Gastrointestinal Dysmotility Evaluation [Test in Focus] - Insights
Divyanshu (Div), Dubey, M.B.B.S, gives an overview of the new Autoimmune Gastrointestinal Dysmotility Evaluation available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to...
Assay enhances and simplifies M-proteins screening: David Murray, M.D., Ph.D. - Insights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASSFIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the...
MayoComplete next-generation sequencing: Transforming comprehensive cancer care - Insights
Offering increased sensitivity and improved accuracy, MayoComplete next-generation testing ensures health care providers understand the distinctive genetic features of their patients’ cancer to make informed decisions to guide their care.